Literature DB >> 12810142

Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients.

Jamshid Ahmadi1.   

Abstract

The aim of this study was to assess the efficacy of methadone compared with buprenorphine maintenance therapy in heroin-dependent patients over a treatment period of 18 weeks. Subjects were randomized to receive either methadone or buprenorphine in a comparative double-blind study and consisted of 164 heroin-dependent male patients who met the DSM-IV criteria for heroin dependence and were seeking treatment. The 164 subjects included 41 patients in 1-mg, 41 patients in 3-mg, and 41 patients in 8-mg dosage group of buprenorphine, and also 41 patients in the 30-mg dosage group of methadone. The mean age was 31.4 years for total buprenorphine group and 33.7 years for methadone group (the mean age differences in 4 groups were not statistically significant). Subjects received buprenorphine at a dose of 1, 3, or 8 mg per day or methadone at a dose of 30 mg per day and were treated in an urban outpatient clinic, offering a 1-hour weekly individual counseling session. Days retained in treatment were measured. Completion rates by buprenorphine dosage group were 29.3% for the 1-mg dose group, 46.3% for the 3-mg dose group, 68.3% for the 8-mg dose group, and 61% for the 30-mg methadone dose group. Retention in the 8-mg dose group was significantly better than in the 1-mg dose group (p=.00041) and in the 3-mg dose group (p=.045); other comparison (1 mg dose with 3 mg dose) was not significant. Methadone group was significantly better than 1mg buprenorphine dose group (p=.004), but was not significantly different from 3 mg buprenorphine dose group (p=.18) or 8 mg buprenorphine dose group (p=.49). The results support the efficacy of buprenorphine for outpatient treatment of heroin dependence and seem to indicate that the highest dose (8 mg) of buprenorphine was the best of the three doses of buprenorphine, and also support the superiority of 30 mg of methadone compared to 1 mg dose of buprenorphine for Iranian heroin-dependent patients to increase their retention in treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810142     DOI: 10.1016/s0740-5472(03)00024-2

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  14 in total

Review 1.  The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence.

Authors:  Steven Simoens; Catriona Matheson; Christine Bond; Karen Inkster; Anne Ludbrook
Journal:  Br J Gen Pract       Date:  2005-02       Impact factor: 5.386

Review 2.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

Review 4.  Opioid dependence.

Authors:  Jacinta O'Shea; Fergus Law; Jan Melichar
Journal:  BMJ Clin Evid       Date:  2009-07-24

Review 5.  Update on the clinical use of buprenorphine: in opioid-related disorders.

Authors:  Simon Ducharme; Ronald Fraser; Kathryn Gill
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

6.  Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.

Authors:  Mohammadali Nikoo; Ehsan Moazen-Zadeh; Nooshin Nikoo; Sanam Javidanbardan; Alireza Kazemi; Fiona Choi; Marc Vogel; Ali Gholami; Saeed Tavakoli; Reza Givaki; Majid Jazani; Fatemeh Mohammadian; Nader Markazi Moghaddam; Nasser Goudarzi; Christian Schutz; Kerry Jang; Shahin Akhondzadeh; Michael Krausz
Journal:  Int J Methods Psychiatr Res       Date:  2019-02-04       Impact factor: 4.035

Review 7.  Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.

Authors:  Jonathan Feelemyer; Don Des Jarlais; Kamyar Arasteh; Abu S Abdul-Quader; Holly Hagan
Journal:  Addiction       Date:  2013-08-15       Impact factor: 6.526

Review 8.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  Methadone treatment in Iranian opiate addicts: a preliminary report.

Authors:  Mahin Eslami Shahrbabaki; Hassan Ziaaddini; Ali Akbar Hagh Doost; Mahdi Ghasemi; Parvin Eslami Shahrbabaki; Roghayeh Alizadeh Nouri; Nasrin Eslami Shahrbabaki
Journal:  Addict Health       Date:  2011 Winter-Spring

Review 10.  Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.

Authors:  Sofie Mauger; Ronald Fraser; Kathryn Gill
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.